Aristotle Capital Boston, LLC released its third-quarter 2025 investor letter, reporting solid results for U.S. small/mid-cap equities. The strategy delivered a 2.57% net return, underperforming the Russell 2500 Index’s 9.00% total return. For more details on the fund’s top picks, check its top five holdings.

Haemonetics Corporation (NYSE:HAE), a medical technology company, was highlighted in Aristotle Capital’s investor letter. The stock had a one-month return of 0.93% and lost 31.99% of its value over the last 52 weeks. On October 31, 2025, Haemonetics Corporation closed at $50.01 per share with a market capitalization of $2.409 billion.

Aristotle Capital noted that Haemonetics Corporation delivered mixed results in the third quarter, beating analyst earnings estimates but posting weaker revenue results. The company’s strong competitive position in the plasmapheresis market and increased investment in R&D are expected to create long-term value for shareholders.

Haemonetics Corporation is not among the 30 most popular stocks among hedge funds, with 29 holding it at the end of the second quarter. The company reported $321 million in revenue for the first fiscal quarter of 2026, down 4% year-over-year. While Haemonetics offers potential as an investment, some AI stocks may have greater upside potential and lower downside risk.

In another article, Haemonetics Corporation was mentioned in a list of the most oversold healthcare stocks in 2025. For more insights, check out hedge fund investor letters from Q3 2025 for additional perspectives from leading investors.

Read more at Yahoo Finance: Should You Hold Haemonetics Corporation (HAE)?